Yu Akahoshi
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 120 publications
Differential impact of GVHD prophylaxis on CMV infection and survival outcomes after cord blood transplantation in the era of letermovir.
Journal: Transplantation and cellular therapy
Published: May 25, 2026
Systemic steroid treatment of grade I acute GVHD increases steroid-refractory GVHD and NRM.
Journal: Blood immunology & cellular therapy
Published: May 15, 2026
Real-World Use of Maribavir for Refractory CMV Infection and Intolerance to Conventional Anti-CMV Agents After Allogeneic Hematopoietic Cell Transplantation.
Journal: Transplantation and cellular therapy
Published: May 07, 2026
Biomarker-driven strategies and challenges in acute graft-versus-host disease clinical trials.
Journal: International journal of hematology
Published: October 02, 2025
Cyclophosphamide and Cyclosporin for GVHD Prevention.
Journal: The New England journal of medicine
Published: October 01, 2025
Optimizing Patient Selection for Reduced Nonrelapse Mortality After Reduced-Intensity Conditioning: A CIBMTR Analysis.
Journal: Transplantation and cellular therapy
Published: September 25, 2025
Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease Severity.
Journal: Transplantation and cellular therapy
Published: July 31, 2025
A win ratio approach for comparing graft-versus-host disease-free, relapse-free survival among alternative donors.
Journal: British journal of haematology
Published: April 25, 2025
Heterogeneity of Survival Benefit Conferred By Letermovir.
Journal: Transplantation and cellular therapy
Published: March 13, 2025
Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group.
Journal: Transplantation and cellular therapy
Published: September 09, 2024
Last Updated: 09/26/2026